

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Feasibility of impact microindentation testing in population-based research

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023959
Article Type:	Research
Date Submitted by the Author:	04-May-2018
Complete List of Authors:	Rufus, Pamela; Deakin University Faculty of Health, School of Medicine Holloway, Kara; Deakin University - Geelong Waterfront Campus, Department of Medicine Diez-Perez, A; University of Barcelona Kotowicz, Mark; Barwon Health, Department of Endocrinology and Diabetes Pasco, Julie; The University of Melbourne, Clinical and Biomedical Sciences: Barwon Health
Keywords:	EPIDEMIOLOGY, Bone diseases < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

View Only

Feasibility of impact microindentation testing in population-based research

Pamela G Rufus¹, Kara L Holloway-Kew¹, Adolfo Diez-Perez², Mark A Kotowicz^{1,3,4}, Julie A Pasco^{1,3,4,5}

¹*Deakin University, Geelong, VIC, Australia.*

²*Department of Internal Medicine, Hospital del Mar-IMIM, Autonomous University of Barcelona and CIBERFES, Instituto Carlos III, Spain.*

³*Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, VIC, Australia.*

⁴*Barwon Health, Geelong, VIC, Australia.*

⁵*Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia*

Corresponding author: Pamela G Rufus. Epi-Centre for Healthy Ageing. IMPACT Strategic Research Centre, PO Box 281, School of Medicine, Deakin University. Geelong 3220 VIC, Australia. Tel: +61 342153323. Email: prufus@deakin.edu.au

ABSTRACT

Objectives The OsteoProbe® measures bone material strength index (BMSi) of cortical bone in living humans using impact microindentation (IMI). Research using this minimally-invasive technique is expanding yet, to-date, there have been no reports about its acceptability in the research setting. In this study we assessed the acceptability and feasibility of using the OsteoProbe® to assess men enrolled in the Geelong Osteoporosis Study.

Design Cross-sectional analysis of data collected in a population-based study.

Setting Barwon Statistical Division, south-eastern Australia, 2016-2018

Methods For 252 of 345 consecutive participants (ages 33-96 years), BMSi was measured using the OsteoProbe® at the mid-tibia. Immediately following measurement, each participant used a visual analogue scale (0-10) to rate the level of discomfort that was anticipated and experienced, their initial reluctance towards the measurement and their willingness to repeat measurement.

Results Reasons for non-measurement in 92 men were needle phobia (n=8), discomfort after first indentation (n=5), skin infections (n=21), excessive soft tissues around the mid-tibia region (n=56), inability to provide informed consent (n=2). Among 252 men who had IMI measures, the expectation for pain during measurement was low (1.54 ± 1.56), as was actual pain experienced (0.38 ± 0.71). Reluctance to undergo measurement was low (0.34 ± 0.93). All participants indicated a willingness to have the measurement performed again. Mean (\pm SD) BMSi was 83.0 ± 6.4 (range 62.3-93.0).

Conclusion In this study, the procedure was well accepted by participants suggesting that IMI testing with the OsteoProbe® is feasible in a research setting.

Keywords: Microindentation, bone material strength index, fractures, OsteoProbe.

Strengths and limitations of this study

- This is the first study to examine the acceptability and feasibility of the OsteoProbe® in a population-based study setting.
- We evaluated the associations between BMSi and age in the largest population-based sample of men so far.
- We cannot exclude the possibility of some bias in the BMSi outcome because of non-participation.

Introduction

The most widely used clinical measurement for ascertainment of fracture risk is bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) (1). However, BMD does not fully explain fracture risk, as the largest absolute number of fragility fractures occur in people without severe deficits in BMD (2,3). Other determinants of bone strength such as bone geometry, microarchitecture and material properties are likely to contribute to fracture risk. Also, clinical factors such as a history of prior fracture, age, exposure to glucocorticoid and other medications, smoking and falls, can contribute independently to fracture risk, and these risk factors can be incorporated into fracture risk algorithms such as FRAX (4), the GARVAN algorithm (5) and the FRISK score (6). Therefore, the goal of much research is to develop techniques to better identify patients at risk of fracture. Using a novel device, the OsteoProbe®, to assess cortical bone material strength index (BMSi) in vivo, impact microindentation (IMI) is one such technique (7). The technical aspects of this device have been discussed in detail elsewhere. (7,8) Its output; the BMSi, is a unitless parameter derived as the ratio of the average indentation distance of repeated measurements made into a reference material, polymethylmetacrylate (PMMA), and into bone (8). The use of this device

1
2
3 in research is growing; and BMSi has reportedly distinguished between patients with
4 different levels of fracture risk in some (9–12) but not all (13) studies, often independently of
5 BMD. These studies have been limited to relatively small sample sizes and have often
6 involved patients selected on the basis of disease.
7
8
9

10
11 Although these data suggest that BMSi might have clinical utility, future research is
12 warranted, particularly using unselected, population-based samples, to assess the performance
13 of IMI for identifying individuals at risk of fracture. As a new, minimally-invasive
14 technology, it is important to gauge the acceptability of the IMI to better understand whether
15 participant groups and volunteers are likely to undergo the procedure in a research setting.
16
17 The aim of this study was to assess the acceptability and feasibility of the OsteoProbe®
18 among men enrolled in the Geelong Osteoporosis Study (GOS).
19
20
21
22
23
24
25
26
27
28
29
30

31 **METHODS**

32 **Patient and Public involvement**

33
34 Study participants were selected at random from the general population and invited to
35 participate; they did not represent a specific patient group. This observational study was
36 designed as part of an ongoing program of research aimed at improving fracture risk
37 assessment. While participants were not involved in developing the research question, we
38 documented their participant experience by questionnaire. Results will be disseminated to
39 participants via a research update which is distributed annually.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Source Population

The GOS is a population-based study situated in a defined region in south-eastern Australia, known as the Barwon Statistical Division (14). An age-stratified, randomly-selected cohort of 1540 men aged 20-97 years was recruited 2001-2006 using the electoral roll as the sampling frame. The cohort is being followed prospectively, with assessments every few years. (14) This analysis focuses on the first 345 men assessed as part of the 15-year follow-up. In conjunction with other clinical measures including bone densitometry, participants were approached to undergo IMI testing and complete a short questionnaire about their experience relating to the technique. The study was approved by the Human Research Ethics Committee at Barwon Health. All participants provided informed consent.

Bone material strength testing

IMI was performed by a trained operator using the OsteoProbe® (Active Life Scientific, Inc., CA, USA). The IMI procedure was explained to participants before measurements were made. Participants were positioned in decubitus supine position, with the leg to be measured rotated to orient the flat surface of the medial tibia diaphysis. The mid distance between the medial border of the tibia plateau and the medial malleolus was marked using a measuring tape. Following a disinfection of the area using a 70% isopropyl alcohol swab, 2% Lidocaine was administered by inserting a syringe both subcutaneously and in the periosteal surface. A sterile probe was then inserted at the marked mid diaphysis, piercing the skin and periosteum until reaching the bone cortex. While maintaining probe contact with the bone surface, as well as orienting the probe perpendicularly to the tibia surface, the outer housing of the device was slid towards the subject's leg to initiate a measurement. After the first measurement, the probe was moved to a new location, at least 2mm away from the prior measurement, to obtain another measurement. In this study, at least 11 indentations were

1
2
3 performed on each subject, of which the first measurement was systematically disregarded
4 followed by 10 valid test indentations. A trained observer assisted the operator by ensuring
5 that the probe was held perpendicular to the tibial surface. The procedure was conducted
6 according to internationally-recognised recommendations for using the Osteoprobe RUO
7 (15). Immediately following measurement, each participant completed a questionnaire that
8 asked them to rate on a visual analogue scale (0-10) the level of pain that was anticipated, the
9 level of pain that was experienced, their initial reluctance towards the measurement and their
10 willingness to undergo the measurement again.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **Statistical Analyses**

25
26 Comparisons between participants included and excluded in analyses were identified using t-
27 tests, and one-way ANOVA for differences in visual analogue scale responses across age
28 groups. Pearson product moment correlation was used to test for a linear correlation between
29 BMSi and age, weight, height and BMI. Statistical analyses were performed using Minitab
30 (version 17; Minitab, State College, PA).
31
32
33
34
35
36
37
38
39
40

41 **RESULTS**

42
43 Of 345 potential participants, exclusions were: needle phobia (n=8), skin infections (n=21),
44 excessive soft tissues around mid-tibia region (n=56), due to discomfort (pressure, no pain)
45 after the first indentation (n=5), unable to provide informed consent (n=2). One participant
46 had IMI after skin infection had been treated. Therefore, 252 participants were included in the
47 subsequent analyses.
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 shows characteristics of study participants included and excluded in the analyses respectively. Participants ranged in age from 33 to 96 years.

BMSi ranged from 62.3 to 93.0. Mean BMSi \pm SD values for age groups 30-49, 50-69 and 70+ years were 81.9 \pm 5.4, 83.7 \pm 6.2 and 81.6 \pm 6.7, respectively. Acceptability scores were similar across all ages (Table 2, Figure 1). The expectation for pain during OsteoProbe® measurement was low, as was actual pain experienced and initial reluctance to undergo measurement. Acceptability of the OsteoProbe® measurement was high; all 252 participants who had a successful measurement indicated a willingness to undergo the measurement again. No adverse events were reported.

There were no correlations detected between BMSi and age ($r=0.070$, $p=0.270$), height ($r=0.068$, $p=0.281$) or weight ($r=-0.078$, $p=0.215$); however, there was a negative correlation between BMSi and BMI ($r=-0.135$, $p=0.032$).

Table 1 Characteristics of the study participants included and excluded in analyses

Characteristics	Included (n=252)	Excluded (n=92)	p Value
Age (yr)	63.2 \pm 12.6	65.5 \pm 15.6	0.2
Weight (kg)	81.2 \pm 10.9	92.9 \pm 19.1	0.6
Height (cm)	174.3 \pm 6.9	173.7 \pm 10.3	0.0
Body Mass Index (kg/m ²)	26.7 \pm 3.1	30.8 \pm 7.8	0.0

Data shown as mean (\pm SD)

Table 2: Feasibility scores for the whole group and according to age

	ALL ages	30-49 yr	50-69 yr	70+ yr	p Value
*Expectation for Pain	1.5 ± 1.6	2.0 ± 1.7	1.6 ± 1.6	1.2 ± 1.5	0.1
*Actual pain experienced	0.4 ± 0.7	0.4 ± 0.8	0.4 ± 0.8	0.3 ± 0.47	0.4
*Level of reluctance	0.3 ± 0.9	0.6 ± 1.0	0.4 ± 1.0	0.2 ± 0.6	0.1

*Questionnaire results for 0-10 visual analogue scale

DISCUSSION

In this study, we observed a high acceptability of IMI; their reluctance to undergo the measurement was low and a majority indicated a willingness to undergo the measurement again.

Although IMI is a minimally invasive procedure, with indentations on the scale of micrometres, a valid concern is the acceptability of the procedure in a research setting, particularly in studies that rely on participants/volunteers from the general population. We report that testing with the device is feasible among participants in our population-based study. The most common reason for exclusion was excessive soft tissues around the mid-tibia. Other reasons for exclusions were skin infections, needle phobia, inability to provide informed consent and discomfort after the first indentation, but these affected only one-tenth of the study participants. Other potential contraindications include prior clinical or stress fracture in the tibia diaphysis, focal tibial lesions and Paget's disease (15); however, to the best of our knowledge, no studies have reported the actual number of exclusions based on these criteria.

1
2
3 In studies using IMI, only two instances of adverse effects have been reported in the
4 literature, one associated with reaction to local anaesthetic and one mild skin infection, in
5 more than 1300 measured individuals (15). To our knowledge, we are the first to document
6 the acceptability of the procedure. Given that the anterior surface of the tibia is pre-treated
7 with a local anaesthetic delivered by subcutaneous injection through the skin and around the
8 periosteum and that the probe of the device is inserted through the skin, subcutaneous soft
9 tissue and periosteum into the cortical bone, it would seem likely that the procedure might
10 seem unpleasant for some study participants. High rates of refusal would introduce bias.
11 However, our results indicate that IMI is generally acceptable, at least for the participants of
12 our study implying that the technique shows promise as a measure of bone material properties
13 in a practical, safe and convenient manner.
14
15
16
17
18
19
20
21
22
23
24
25

26
27 Furthermore, we investigated participants from a wide age range and observed similar
28 feasibility scores across age groups ranging from 30-49, 50-69 to 70 years and older. The
29 men in the oldest category tended to report a lower expectation for pain, experienced less
30 pain and were less reluctant to undergo the measurement, but these differences were not
31 statistically significant.
32
33
34
35
36
37
38

39 In this study, we did not observe a correlation between BMSi and age, corresponding to two
40 studies by Duarte Sosa et al. in which no association was detected between age and BMSi in
41 42 Norwegian and 46 Spanish women (16) and among 30 women with previous stress
42 fractures and 30 normal controls (17). By contrast, an inverse association between age and
43 BMSi has been reported for 90 patients (male and female) with low bone mass, ($r=-0.539$;
44 $p<0.001$) and in a case-control study of 48 acromegaly patients and 44 controls (male and
45 female), there was a positive association for patients with acromegaly ($r=0.291$, $p = 0.045$)
46 and an inverse relationship for the controls ($r=-0.457$, $p=0.002$) (18). The reason for lack of
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 consistency in results is not clear but likely reflects differences in study design and study
4
5 populations.
6

7
8 Moreover, no correlations of BMSi with height, weight were found but we observed a
9
10 negative correlation between BMSi and BMI. Similarly, Sundh et al. (19) reported a negative
11
12 correlation ($r=-0.17$, $p=0.01$) between BMSi and BMI in a population-based study of 202
13
14 women between 75 and 80 years of age, and Rudang et al. (13) reported a weak inverse
15
16 correlation ($r=-0.14$, $p=0.04$) between BMSi and weight in a population-based cohort of 211
17
18 women between 75 and 80 years of age, and, in accordance with our findings, there was no
19
20 association with height.
21

22
23 To our knowledge, this is the first study to examine the acceptability and feasibility of the
24
25 OsteoProbe® in a population-based study. Unlike most of the previous studies, this study is
26
27 population-based and not selected on the basis of disease status. The outcome will thus be
28
29 relevant for the general population. In this study, one operator conducted the IMI
30
31 measurements and an observer was present to ensure the procedure was performed according
32
33 to the standardised procedure.
34
35

36
37 However, we acknowledge the following limitations. IMI could not be performed in
38
39 individuals with substantial amounts of soft tissue around the mid-tibia region, nor in
40
41 individuals with skin disorders or infections in at the site of measurement and this may have
42
43 biased our results. It should be noted that there are also drawbacks with other technologies.
44
45 For example, a weight limitation (typically 120kg or 300lb) and narrow bed width (~60 cm)
46
47 necessitates exclusion of large individuals from assessment with DXA (20). Furthermore,
48
49 individuals with spinal abnormalities and those affected by devices such as plates, screws,
50
51 silicone implants and prostheses can compromise the interpretation of DXA scans (21–24). In
52
53
54
55
56
57
58
59
60

our study, we investigated men only, and recognise that the observations may not be generalisable to women or other populations.

In conclusion, IMI was well accepted by participants suggesting that testing with the OsteoProbe® is feasible in a research setting. Further assessment of the clinical utility of this technology for assessing fracture risk is warranted and currently in progress.

Funding Statement

The Geelong Osteoporosis Study was supported by the National health and Medical Research Council (NHMRC; projects 299831, 628582).and Amgen-GSK OA-ANZBMS, but they played no role in the collection or interpretation of data.

Competing Interests

PGR is supported by Deakin University Postgraduate Industry Research Scholarship. KLH-K is supported by an Alfred Deakin Postdoctoral Research Fellowship. AD-P owns shares of Active Life Scientific, Inc., the manufacturer of the RPI device. MAK and JAP are recipients of grants from the NHMRC and Amgen-GSK OA-ANZBMS.

Authors' contributions

PGR performed the indentation measurements in the presence of another trained observer (KLH-K) and drafted the manuscript. KLH-K assisted with taking measurements and administered questionnaires. AD-P assisted with training to use the OsteoProbe device and provided advice on measurement technique. MAK and JAP conceived and designed the study. JAP secured ethics approval. All authors interpreted the data, guided and reviewed the manuscript. All authors read and approved the final manuscript.

Data sharing statement

The datasets used and analysed during the current study are available from the corresponding author on reasonable request. Requests can be sent to gos@barwonhealth.org.au.

Ethics approval and consent to participate

This project has been approved by Human Research Ethics Committee at Barwon Health. All participants gave written informed consent to participate in the study.

Acknowledgements

We thank Dr Peter Burks from Active Life Scientific, Inc. for his technical guidance

References

1. Allen MR, McNerny EMB, Organ JM, Wallace JM. True gold or pyrite: A review of reference point indentation for assessing bone mechanical properties in vivo. *J Bone Miner Res* 2015;30:1539–50.
2. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. *Osteoporos Int* 2006;17:1404–9.
3. Pasco JA, Lane SE, Brennan SL, Timney EN, Bucki-Smith G, Dobbins AG, et al. Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data. *Osteoporos Int*. 2014 ;25:857–62.
4. Watts NB. The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice. *J Womens Health*. 2011;20:525–31.
5. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen T V. Development of a nomogram for individualizing hip fracture risk in men and women. *Osteoporos Int* 2007;18:1109–17.
6. Henry MJ, Pasco JA, Sanders KM, Nicholson GC, Kotowicz MA. Fracture risk (FRISK) score : Geelong Osteoporosis Study. *Radiology*. 2006;241:190–6.
7. Randall C, Bridges D, Guerri R, Nogues X, Puig L, Torres E, et al. Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. *J Med Device* 2013;7:410051–6.
8. Bridges D, Randall C, Hansma PK. A new device for performing reference point indentation without a reference probe. *Rev Sci Instrum*. 2012;83: 044301-8.

- 1
2
3 9. Malgo F, Hamdy NAT, Papapoulos SE, Appelman-Dijkstra NM. Bone material
4 strength as measured by microindentation in vivo is decreased in patients with fragility
5 fractures independently of bone mineral density. *J Clin Endocrinol Metab.*
6 2015;100:2039–45.
7
8
- 9
10
11
12 10. Malgo F. Bone material strength index as measured by impact microindentation is low
13 in patients with fractures irrespective of fracture site. *Osteoporosis International*;
14 2017;24:33–7.
15
16
- 17
18
19 11. Rozental TD, Walley KC, Demissie S, Caksa S, Martinez-betancourt A, Parker AM, et
20 al. Bone Material Strength Index as Measured by Impact Radius and Hip Fractures. *J*
21 *Bone Miner Res.* 2017;176:1–6.
22
23
- 24
25
26 12. With W, Radius D, Rozental TD, Walley KC, Demissie S, Caksa S. Bone Material
27 Strength Index as Measured by Impact Microindentation in Postmenopausal Bone
28 Material Strength Index as Measured by Impact. *J Bone Miner Res* 2018;33:621-626.
29
30
- 31
32
33 13. Rudäng R, Zoulakis M, Sundh D, Brisby H, Diez-Perez A, Johansson L, et al. Bone
34 material strength is associated with areal BMD but not with prevalent fractures in older
35 women. *Osteoporos Int.* 2016;27:1585–92.
36
37
- 38
39
40 14. Pasco JA, Nicholson GC, Kotowicz MA. Cohort Profile: Geelong Osteoporosis Study
41 *Int J Epidemiol* 2012; 41: 1565-1575.
42
43
- 44
45
46 15. Diez-Perez A, Bouxsein ML, Eriksen EF, Khosla S, Nyman JS, Papapoulos S, et al.
47 Technical note: Recommendations for a standard procedure to assess cortical bone at
48 the tissue-level in vivo using impact microindentation. *Bone Reports.* 2016;5:181–5.
49
50
- 51
52
53 16. Duarte Sosa D, Vilaplana L, Güerri R, Nogués X, Wang-Fagerland M, Diez-Perez A,
54 et al. Are the High Hip Fracture Rates Among Norwegian Women Explained by
55
56
57

- 1
2
3 Impaired Bone Material Properties? *J Bone Miner Res.* 2015;30:1784–9.
4
5
6 17. Duarte Sosa D, Fink Eriksen E. Women with previous stress fractures show reduced
7
8 bone material strength. *Acta Orthop.* 2016;3674:1–6.
9
10
11 18. Malgo F, Hamdy NAT, Rabelink TJ, Kroon HM, Claessen KMJA, Pereira AM, et al.
12
13 Bone material strength index as measured by impact microindentation is altered in
14
15 patients with acromegaly. *Eur J Endocrinol.* 2017;176:339–47.
16
17
18 19. Sundh D, Rudang R, Zoulakis M, Nilsson AG, Darelid A, Lorentzon M. A High
19
20 Amount of Local Adipose Tissue Is Associated with High Cortical Porosity and Low
21
22 Bone Material Strength in Older Women. *J Bone Miner Res.* 2016;31:749–57.
23
24
25 20. Rothney MP, Brychta RJ, Schaefer E V, Chen KY, Monica C. Body Composition
26
27 Measured by Dual-energy X-ray Absorptiometry Half-body Scans in Obese Adults
28
29 *Obesity (Silver Spring)* 2009;17(6):1281–6.
30
31
32 21. Gould H1, Brennan SL, Kotowicz MA, Nicholson GC PJ. Total and appendicular lean
33
34 mass reference ranges for Australian men and women: the Geelong Osteoporosis
35
36 Study. *Calcif Tissue Int.* 2014;94:363–72.
37
38
39 22. Henry MJ, Pasco JA, Korn S, Gibson JE. Bone mineral density reference ranges for
40
41 Australian men : Geelong Osteoporosis Study. *Osteoporos Int* 2010;909–17.
42
43
44 23. Kalichman L1, Li L, Kim DH, Guermazi A, Berkin V, O'Donnell CJ, Hoffmann U,
45
46 Cole R HD. Facet joint osteoarthritis and low back pain in the community-based
47
48 population. *Spine* 2008;33:2560–5.
49
50
51 24. Szulc P, Marchand, F, Duboeuf, F DP. Cross-sectional assessment of age-related bone
52
53 loss in men: the MINOS study. *Bone.* 2000;26:123–9.
54
55
56
57
58
59
60

Figure 1: An interval plot of 0-10 Visual Analogue scale results, according to age

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: An interval plot of 0-10 Visual Analogue scale results, according to age
127x84mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-7
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-7
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Feasibility and Tolerability of impact microindentation testing in population-based research

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023959.R1
Article Type:	Research
Date Submitted by the Author:	13-Aug-2018
Complete List of Authors:	Rufus, Pamela; Deakin University Faculty of Health, School of Medicine Holloway, Kara; Deakin University - Geelong Waterfront Campus, Department of Medicine Diez-Perez, A; University of Barcelona Kotowicz, Mark; Barwon Health, Department of Endocrinology and Diabetes Pasco, Julie; The University of Melbourne, Clinical and Biomedical Sciences: Barwon Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology
Keywords:	EPIDEMIOLOGY, Bone diseases < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

1
2
3 **Feasibility and Tolerability of impact microindentation testing in population-based**
4 **research**

5
6
7 Pamela G Rufus¹, Kara L Holloway-Kew¹, Adolfo Diez-Perez², Mark A Kotowicz^{1,3,4}, Julie
8
9 A Pasco^{1,3,4,5}

10
11
12 ¹*Deakin University, Geelong, VIC, Australia.*

13 ²*Department of Internal Medicine, Hospital del Mar-IMIM, Autonomous University of*
14 *Barcelona and CIBERFES, Instituto Carlos III, Spain.*

15 ³*Department of Medicine-Western Health, Melbourne Medical School, The University of*
16 *Melbourne, VIC, Australia.*

17 ⁴*Barwon Health, Geelong, VIC, Australia.*

18 ⁵*Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC,*
19 *Australia*

20
21
22
23
24
25
26
27 Corresponding author: Pamela G Rufus. Epi-Centre for Healthy Ageing. IMPACT Strategic
28 Research Centre, PO Box 281, School of Medicine, Deakin University. Geelong 3220 VIC,
29 Australia. Tel: +61 342153323. Email: prufus@deakin.edu.au

ABSTRACT

Objectives The OsteoProbe® measures bone material strength index (BMSi) of cortical bone in living humans using impact microindentation (IMI). Research using this minimally-invasive technique is expanding yet, to-date, there have been no reports about its feasibility in the research setting. In this study we assessed the feasibility and tolerability of using the OsteoProbe® in men enrolled in the Geelong Osteoporosis Study.

Design Cross-sectional analysis of data collected in a population-based study.

Setting Barwon Statistical Division, south-eastern Australia, 2016-2018

Methods For 252 of 345 consecutive participants (ages 33-96 years), BMSi was measured using the OsteoProbe® at the mid-tibia. Immediately following measurement, each participant used a visual analogue scale (0-10) to rate the level of discomfort that was anticipated and experienced, their initial reluctance towards the measurement and their willingness to repeat measurement.

Results Reasons for non-measurement in 92 men were needle phobia (n=8), discomfort after first indentation (n=5), skin infections (n=21), excessive soft tissues around the mid-tibia region (n=56), inability to provide informed consent (n=2). Among 252 men who had IMI measures, the expectation for pain during measurement was low (1.54 ± 1.56), as was actual pain experienced (0.38 ± 0.71). Reluctance to undergo measurement was low (0.34 ± 0.93). All participants indicated a willingness to have the measurement performed again. Mean (\pm SD) BMSi was 83.0 ± 6.4 (range 62.3-93.0).

Conclusion In this study, the procedure was well accepted by participants suggesting that IMI testing with the OsteoProbe® is feasible in a research setting.

Keywords: Microindentation, bone material strength index, fractures, OsteoProbe.

Strengths and limitations of this study

- This is the first study to examine the feasibility and tolerability of the OsteoProbe® in a population-based study setting.
- We evaluated the associations between BMSi and age in the largest population-based sample of men so far.
- We cannot exclude the possibility of some bias in the BMSi outcome because of non-participation.

Introduction

The most widely used clinical measurement for ascertainment of fracture risk is bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) (1). However, BMD does not fully explain fracture risk, as the largest absolute number of fragility fractures occur in people without severe deficits in BMD (2,3). Other determinants of bone strength such as bone geometry, microarchitecture and material properties are likely to contribute to fracture risk. Also, clinical factors such as a history of prior fracture, age, exposure to glucocorticoid and other medications, smoking and falls, can contribute independently to fracture risk, and these risk factors can be incorporated into fracture risk algorithms such as FRAX (4), the GARVAN algorithm (5) and the FRISK score (6). Therefore, the goal of much research is to develop techniques to better identify patients at risk of fracture. Using a novel device, the OsteoProbe®, to assess cortical bone material properties in vivo, impact microindentation (IMI) is one such technique (7). The OsteoProbe® measures Bone Material Strength Index (BMSi). This parameter quantifies how well a bone resists microindentation. BMSi is defined as 100 times the ratio of the indentation distance from the impact to a calibration material, PMMA (poly methyl methacrylate), divided by the indentation distance from the impact into

1
2
3 the bone. As the probe indents the bone, it induces microfractures. The more easily the bone
4 is fractured, the deeper the probe indents and the lower the BMSi. The technical aspects of
5 this device have been described in detail in the initial scientific instrumentation papers (7, 8).
6
7 The use of this device in research is growing; and BMSi has reportedly distinguished between
8 patients with different levels of fracture risk in some (9–12) but not all (13) studies, often
9 independently of BMD. These studies have been limited to relatively small sample sizes and
10 have often involved patients selected on the basis of disease.

11
12 Although these data suggest that BMSi might have clinical utility, future research is
13 warranted, particularly using unselected, population-based samples, to assess the performance
14 of IMI for identifying individuals at risk of fracture. As a new, minimally invasive
15 technology, it is important to gauge the tolerability of the IMI to better understand whether
16 participant groups and volunteers are likely to undergo the procedure in a research setting.
17
18 The aim of this study was to assess the feasibility and tolerability of the OsteoProbe® among
19 men enrolled in the Geelong Osteoporosis Study (GOS).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **METHODS**

39 **Patient and Public involvement**

40
41 Study participants were selected at random from the general population and invited to
42 participate; they did not represent a specific patient group. This observational study was
43 designed as part of an ongoing program of research aimed at improving fracture risk
44 assessment. While participants were not involved in developing the research question, we
45 documented their participant experience by questionnaire. Results will be disseminated to
46 participants via a research update, which is distributed annually. **Source Population**

1
2
3 The GOS is a population-based study situated in a defined region in south-eastern Australia,
4 known as the Barwon Statistical Division (14). An age-stratified, randomly-selected cohort of
5 1540 men aged 20-97 years was recruited 2001-2006 using the electoral roll as the sampling
6 frame. The cohort is being followed prospectively, with assessments every few years (14).
7
8 This analysis focuses on the first 345 men assessed as part of the 15-year follow-up. In
9 conjunction with other clinical measures including bone densitometry, participants were
10 approached to undergo IMI testing and complete a short questionnaire about their experience
11 relating to the technique. The study was approved by the Human Research Ethics Committee
12 at Barwon Health (00/56-E7). All participants provided informed consent.
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **Bone material strength testing**

27
28
29 IMI was performed by a trained operator using the OsteoProbe® (Active Life Scientific, Inc.,
30 CA, USA). The IMI procedure was explained to participants before measurements were
31 made. They were informed that the procedure is a new technique that might assess the
32 resistance of bones to fractures by inducing micro fractures on a small area of the tibia.
33 Furthermore, participants were told the procedure is minimally invasive and does not affect
34 the ability of the individual to walk immediately after. They were then given the option to
35 participate or not participate in the study.
36
37
38
39
40
41
42
43
44

45 Participants who chose to participate in the study were positioned in decubitus supine
46 position, with the leg to be measured rotated to orient the flat surface of the medial tibia
47 diaphysis. The mid distance between the medial border of the tibia plateau and the medial
48 malleolus were marked using a measuring tape. Following a disinfection of the area using a
49 70% isopropyl alcohol swab, 2% Lidocaine was administered by inserting a syringe both
50 subcutaneously and in the periosteal surface. A sterile probe was then inserted at the marked
51
52
53
54
55
56
57
58
59
60

1
2
3 mid diaphysis, piercing the skin and periosteum until reaching the bone cortex. While
4 maintaining probe contact with the bone surface, as well as orienting the probe
5 perpendicularly to the tibia surface, the outer housing of the device was slid towards the
6 subject's leg to initiate a measurement. After the first measurement, the probe was moved to
7 a new location, at least 2mm away from the prior measurement, to obtain another
8 measurement. In this study, at least 11 indentations were performed on each subject, of which
9 the first measurement was systematically disregarded followed by 10 valid test indentations.
10 A trained observer assisted the operator by ensuring that the probe was held perpendicular to
11 the tibial surface. The procedure was conducted according to internationally-recognised
12 recommendations for using the Osteoprobe RUO (15). Immediately following measurement,
13 each participant completed a questionnaire that asked them to rate on a visual analogue scale
14 (0-10) the level of pain that was anticipated, the level of pain that was experienced, their
15 initial reluctance towards the measurement and their willingness to undergo the measurement
16 again. The visual analogue scale is a valid, reliable and simple tool used to assess variations
17 in pain intensity (16,17)

38 39 **Statistical Analyses**

40
41 Comparisons between participants included and excluded in analyses were identified using t-
42 tests, and one-way ANOVA for differences in visual analogue scale responses across age
43 groups. Pearson product moment correlation was used to test for a linear correlation between
44 BMSi and age, weight, height and BMI. Statistical analyses were performed using Minitab
45 (version 17; Minitab, State College, PA).

RESULTS

Of 345 potential participants, exclusions were: needle phobia (n=8), existing skin infections (n=21), excessive soft tissues around mid-tibia region (n=56), due to discomfort (pressure, no pain) after the first indentation (n=5), unable to provide informed consent (n=2). One participant had IMI after skin infection had been treated. Therefore, 252 participants were included in the subsequent analyses.

Table 1 shows characteristics of study participants included and excluded in the analyses respectively. Participants ranged in age from 33 to 96 years.

BMSi ranged from 62.3 to 93.0. Mean BMSi±SD values for age groups 30-49, 50-69 and 70+ years were 81.9±5.4, 83.7±6.2 and 81.6±6.7, respectively. The average BMI of participants excluded due to soft tissues was 33.4 ± 5.6.

Tolerability scores were normally distributed and similar across all ages (Table 2, Figure 1). The expectation for pain during OsteoProbe® measurement was low, as was actual pain experienced and initial reluctance to undergo measurement. Tolerability of the OsteoProbe® measurement was high; all 252 participants who had a successful measurement indicated a willingness to undergo the measurement again. No adverse events were reported.

There were no correlations detected between BMSi and age ($r= 0.070$, $p=0.270$), height ($r=0.068$, $p= 0.281$) or weight ($r= -0.078$, $p= 0.215$); however, there was a negative correlation between BMSi and BMI ($r=-0.135$, $p=0.032$).

Table 1 Characteristics of the study participants included and excluded in analyses

Characteristics	Included (n=252)	Excluded (n=92)	<i>p</i> Value
Age (yr)	63.2 ± 12.6	65.5 ± 15.6	0.163
Weight (kg)	81.2 ± 10.9	92.9 ± 19.1	<0.001
Height (cm)	174.3 ± 6.9	173.7 ± 10.3	0.983
Body Mass Index (kg/m ²)	26.7 ± 3.1	30.8 ± 7.8	<0.001

Data shown as mean (±SD)

Table 2: Tolerability scores for the whole group and according to age

	ALL ages	30-49 yr	50-69 yr	70+ yr	<i>p</i> Value
*Expectation for Pain	1.5 ± 1.6	2.0 ± 1.7	1.6 ± 1.6	1.2 ± 1.5	0.070
*Actual pain experienced	0.4 ± 0.7	0.4 ± 0.8	0.4 ± 0.8	0.3 ± 0.47	0.462
*Level of reluctance	0.3 ± 0.9	0.6 ± 1.0	0.4 ± 1.0	0.2 ± 0.6	0.136

*Questionnaire results for 0-10 visual analogue scale

DISCUSSION

In this study, we observed a high tolerability of IMI; reluctance to undergo the measurement was low and while there may be a potential concern for possible harm to the bone, all participants who had a successful measurement indicated a willingness to undergo the measurement again.

Although IMI is a minimally invasive procedure, with indentations on the scale of micrometres, a valid concern is the tolerability of the procedure in a research setting,

1
2
3 particularly in studies that rely on participants/volunteers from the general population. We
4 report that testing with the device is feasible among participants in our population-based
5 study. The most common reason for exclusion was excessive soft tissues around the mid-
6 tibia. Other reasons for exclusions were skin infections, needle phobia, inability to provide
7 informed consent and discomfort after the first indentation, but these affected only one-tenth
8 of the study participants. Other potential contraindications include prior clinical or stress
9 fracture in the tibia diaphysis, focal tibial lesions and Paget's disease (15); however, to the
10 best of our knowledge, no studies have reported the actual number of exclusions based on
11 these criteria.
12
13
14
15
16
17
18
19
20
21
22

23 In studies using IMI, only two instances of adverse effects have been reported in the
24 literature, one associated with reaction to local anaesthetic and one mild skin infection, in
25 more than 1300 measured individuals (15). To our knowledge, we are the first to document
26 the tolerability of the procedure. Given that the anterior surface of the tibial is pre-treated
27 with a local anaesthetic delivered by subcutaneous injection through the skin and around the
28 periosteum and that the probe of the device is inserted through the skin, subcutaneous soft
29 tissue and periosteum into the cortical bone, it would seem likely that the procedure might
30 seem unpleasant for some study participants. High rates of refusal would introduce bias.
31 However, our results indicate that IMI is generally acceptable, at least for the participants of
32 our study implying that the technique shows promise as a measure of bone material properties
33 in a practical, safe and convenient manner.
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Furthermore, we investigated participants from a wide age range and observed similar
48 tolerability scores across age groups ranging from 30-49, 50-69 to 70 years and older. The
49 men in the oldest category tended to report a lower expectation for pain, experienced less
50 pain and were less reluctant to undergo the measurement, but these differences were not
51 statistically significant.
52
53
54
55
56
57
58
59
60

1
2
3 In this study, we did not observe a correlation between BMSi and age, corresponding to two
4 studies by Duarte Sosa et al. in which no association was detected between age and BMSi in
5 42 Norwegian and 46 Spanish women (18) and among 30 women with previous stress
6 fractures and 30 normal controls (19). By contrast, an inverse association between age and
7 BMSi has been reported for 90 patients (male and female) with low bone mass, ($r=-0.539$;
8 $p<0.001$) and in a case-control study of 48 acromegaly patients and 44 controls (male and
9 female), there was a positive association for patients with acromegaly ($r=0.291$, $p = 0.045$)
10 and an inverse relationship for the controls ($r=-0.457$, $p=0.002$) (20). The reason for lack of
11 consistency in results is not clear but likely reflects differences in study design and study
12 populations.
13
14
15
16
17
18
19
20
21
22
23

24
25 Moreover, no correlations of BMSi with height, weight were found but we observed a
26 negative correlation between BMSi and BMI. Similarly, Sundh et al. (21) reported a negative
27 correlation ($r=-0.17$, $p=0.01$) between BMSi and BMI in a population-based study of 202
28 women between 75 and 80 years of age, and Rudang et al. (13) reported a weak inverse
29 correlation ($r=-0.14$, $p=0.04$) between BMSi and weight in a population-based cohort of 211
30 women between 75 and 80 years of age, and, in accordance with our findings, there was no
31 association with height.
32
33
34
35
36
37
38
39
40

41 To our knowledge, this is the first study to examine the tolerability and feasibility of the
42 OsteoProbe® in a population-based study. Unlike most of the previous studies, this study is
43 population-based and not selected on the basis of disease status. The outcome will thus be
44 relevant for the general population. In this study, one operator conducted the IMI
45 measurements and an observer was present to ensure the procedure was performed according
46 to the standardised procedure.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 However, we acknowledge the following limitations. IMI could not be performed in
4 individuals with substantial amounts of soft tissue around the mid-tibia region, nor in
5 individuals with skin disorders or infections in at the site of measurement and this may have
6 biased our results. It should be noted that there are also drawbacks with other technologies.
7 For example, a weight limitation (typically 120kg or 300lb) and narrow bed width (~60 cm)
8 necessitates exclusion of large individuals from assessment with DXA (22). Furthermore,
9 individuals with spinal abnormalities and those affected by devices such as plates, screws,
10 silicone implants and prostheses can compromise the interpretation of DXA scans (23–26). In
11 our study, we investigated men only, and recognise that the observations may not be
12 generalisable to women or other populations.
13
14
15
16
17
18
19
20
21
22
23

24
25 In conclusion, IMI was well accepted by participants suggesting that testing with the
26 OsteoProbe® is feasible in a research setting. Further assessment of the clinical utility of this
27 technology for assessing fracture risk is warranted and currently in progress.
28
29
30
31
32
33
34

35 **Funding Statement**

36
37
38 The Geelong Osteoporosis Study was supported by the National health and Medical Research
39 Council (NHMRC; projects 299831, 628582).and Amgen-GSK OA-ANZBMS, but they
40 played no role in the collection or interpretation of data.
41
42
43
44

45 **Competing Interests**

46
47
48 PGR is supported by Deakin University Postgraduate Industry Research Scholarship. KLH-K
49 is supported by an Alfred Deakin Postdoctoral Research Fellowship. AD-P owns shares of
50 Active Life Scientific, Inc., the manufacturer of the RPI device. MAK and JAP are recipients
51 of grants from the NHMRC and Amgen-GSK OA-ANZBMS.
52
53
54
55
56
57
58
59
60

Authors' contributions

PGR performed the indentation measurements in the presence of another trained observer (KLH-K) and drafted the manuscript. KLH-K assisted with taking measurements and administered questionnaires. AD-P assisted with training to use the OsteoProbe device and provided advice on measurement technique. MAK and JAP conceived and designed the study. JAP secured ethics approval. All authors interpreted the data, guided and reviewed the manuscript. All authors read and approved the final manuscript.

Data sharing statement

The datasets used and analysed during the current study are available from the corresponding author on reasonable request. Requests can be sent to goss@barwonhealth.org.au.

Ethics approval and consent to participate

This project has been approved by Human Research Ethics Committee at Barwon Health. All participants gave written informed consent to participate in the study.

Acknowledgements

We thank Dr Peter Burks from Active Life Scientific, Inc. for his technical guidance

References

1. Allen MR, McNerny EMB, Organ JM, Wallace JM. True gold or pyrite: A review of reference point indentation for assessing bone mechanical properties in vivo. *J Bone Miner Res* 2015;30:1539–50.
2. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. *Osteoporos Int* 2006;17:1404–9.
3. Pasco JA, Lane SE, Brennan SL, Timney EN, Bucki-Smith G, Dobbins AG, et al. Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data. *Osteoporos Int*. 2014 ;25:857–62.
4. Watts NB. The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice. *J Womens Health*. 2011;20:525–31.
5. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen T V. Development of a nomogram for individualizing hip fracture risk in men and women. *Osteoporos Int* 2007;18:1109–17.
6. Henry MJ, Pasco JA, Sanders KM, Nicholson GC, Kotowicz MA. Fracture risk (FRISK) score : Geelong Osteoporosis Study. *Radiology*. 2006;241:190–6.
7. Randall C, Bridges D, Guerri R, Nogues X, Puig L, Torres E, et al. Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. *J Med Device* 2013;7:410051–6.
8. Bridges D, Randall C, Hansma PK. A new device for performing reference point indentation without a reference probe. *Rev Sci Instrum*. 2012;83: 044301-8.

- 1
2
3 9. Malgo F, Hamdy NAT, Papapoulos SE, Appelman-Dijkstra NM. Bone material
4 strength as measured by microindentation in vivo is decreased in patients with fragility
5 fractures independently of bone mineral density. *J Clin Endocrinol Metab.*
6 2015;100:2039–45.
7
8
- 9
10
11
12 10. Malgo F. Bone material strength index as measured by impact microindentation is low
13 in patients with fractures irrespective of fracture site. *Osteoporosis International*;
14 2017;24:33–7.
15
16
- 17
18
19 11. Rozental TD, Walley KC, Demissie S, Caksa S, Martinez-betancourt A, Parker AM, et
20 al. Bone Material Strength Index as Measured by Impact Radius and Hip Fractures. *J*
21 *Bone Miner Res.* 2017;176:1–6.
22
23
- 24
25
26 12. With W, Radius D, Rozental TD, Walley KC, Demissie S, Caksa S. Bone Material
27 Strength Index as Measured by Impact Microindentation in Postmenopausal Bone
28 Material Strength Index as Measured by Impact. *J Bone Miner Res* 2018;33:621-626.
29
30
- 31
32
33 13. Rudäng R, Zoulakis M, Sundh D, Brisby H, Diez-Perez A, Johansson L, et al. Bone
34 material strength is associated with areal BMD but not with prevalent fractures in older
35 women. *Osteoporos Int.* 2016;27:1585–92.
36
37
- 38
39
40 14. Pasco JA, Nicholson GC, Kotowicz MA. Cohort Profile: Geelong Osteoporosis Study
41 *Int J Epidemiol* 2012; 41: 1565-1575.
42
43
- 44
45
46 15. Diez-Perez A, Bouxsein ML, Eriksen EF, Khosla S, Nyman JS, Papapoulos S, et al.
47 Technical note: Recommendations for a standard procedure to assess cortical bone at
48 the tissue-level in vivo using impact microindentation. *Bone Reports.* 2016;5:181–5.
49
50
- 51
52
53 16. Chapman CR, Casey KL, Dubner R, Foley KM, Gracely RH, Reading AE. Pain
54 Measurement: an overview. *Pain.* 1985;22(1):1–31.
55
56
57
58
59
60

17. Gallagher EJ, Bijur PE, Latimer C, Silver W. Reliability and validity of a visual analog scale for acute abdominal pain in the ED. *Am J Emerg Med.* 2002;20(4):287–90.
18. Duarte Sosa D, Vilaplana L, Güerri R, Nogués X, Wang-Fagerland M, Diez-Perez A, et al. Are the High Hip Fracture Rates Among Norwegian Women Explained by Impaired Bone Material Properties? *J Bone Miner Res.* 2015;30:1784–9.
19. Duarte Sosa D, Fink Eriksen E. Women with previous stress fractures show reduced bone material strength. *Acta Orthop.* 2016;3674:1–6.
20. Malgo F, Hamdy NAT, Rabelink TJ, Kroon HM, Claessen KMJA, Pereira AM, et al. Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. *Eur J Endocrinol.* 2017;176:339–47.
21. Sundh D, Rudang R, Zoulakis M, Nilsson AG, Darelid A, Lorentzon M. A High Amount of Local Adipose Tissue Is Associated with High Cortical Porosity and Low Bone Material Strength in Older Women. *J Bone Miner Res.* 2016;31:749–57.
22. Rothney MP, Brychta RJ, Schaefer E V, Chen KY, Monica C. Body Composition Measured by Dual-energy X-ray Absorptiometry Half-body Scans in Obese Adults *Obesity (Silver Spring)* 2009;17(6):1281–6.
23. Gould H1, Brennan SL, Kotowicz MA, Nicholson GC PJ. Total and appendicular lean mass reference ranges for Australian men and women: the Geelong Osteoporosis Study. *Calcif Tissue Int.* 2014;94:363–72.
24. Henry MJ, Pasco JA, Korn S, Gibson JE. Bone mineral density reference ranges for Australian men : Geelong Osteoporosis Study. *Osteoporos Int* 2010;909–17.
25. Kalichman L1, Li L, Kim DH, Guermazi A, Berkin V, O'Donnell CJ, Hoffmann U,

1
2
3 Cole R HD. Facet joint osteoarthritis and low back pain in the community-based
4 population. *Spine* 2008;33:2560–5.
5
6

- 7
8 26. Szulc P, Marchand, F, Duboeuf, F DP. Cross-sectional assessment of age-related bone
9 loss in men: the MINOS study. *Bone*. 2000;26:123–9.
10
11
12
13
14
15
16
17
18

19 **Figure 1: An interval plot of 0-10 Visual Analogue scale results, according to age**
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: An interval plot of 0-10 Visual Analogue scale results, according to age
101x135mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-7
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-7
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Feasibility and Tolerability of Bone Impact Microindentation Testing: a cross-sectional, population-based study in Australia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023959.R2
Article Type:	Research
Date Submitted by the Author:	05-Sep-2018
Complete List of Authors:	Rufus, Pamela; Deakin University Faculty of Health, School of Medicine Holloway, Kara; Deakin University - Geelong Waterfront Campus, Department of Medicine Diez-Perez, A; University of Barcelona Kotowicz, Mark; Barwon Health, Department of Endocrinology and Diabetes Pasco, Julie; The University of Melbourne, Clinical and Biomedical Sciences: Barwon Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology
Keywords:	EPIDEMIOLOGY, Bone diseases < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

1
2
3 **Feasibility and Tolerability of Bone Impact Microindentation Testing: a cross-sectional,**
4 **population-based study in Australia**
5

6
7 Pamela G Rufus¹, Kara L Holloway-Kew¹, Adolfo Diez-Perez², Mark A Kotowicz^{1,3,4}, Julie
8
9 A Pasco^{1,3,4,5}
10

11
12 ¹*Deakin University, Geelong, VIC, Australia.*

13 ²*Department of Internal Medicine, Hospital del Mar-IMIM, Autonomous University of*
14 *Barcelona and CIBERFES, Instituto Carlos III, Spain.*

15 ³*Department of Medicine-Western Health, Melbourne Medical School, The University of*
16 *Melbourne, VIC, Australia.*

17
18 ⁴*Barwon Health, Geelong, VIC, Australia.*

19 ⁵*Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC,*
20 *Australia*
21

22
23
24
25
26
27 Corresponding author: Pamela G Rufus. Epi-Centre for Healthy Ageing. IMPACT Strategic
28 Research Centre, PO Box 281, School of Medicine, Deakin University. Geelong 3220 VIC,
29 Australia. Tel: +61 342153323. Email: prufus@deakin.edu.au
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives The OsteoProbe® measures bone material strength index (BMSi) of cortical bone in living humans using impact microindentation (IMI). Research using this minimally-invasive technique is expanding yet, to-date, there have been no reports about its feasibility in the research setting. In this study, we assessed the feasibility and tolerability of using the OsteoProbe® in men enrolled in the Geelong Osteoporosis Study.

Design Cross-sectional analysis of data collected in a population-based study.

Setting Barwon Statistical Division, south-eastern Australia, 2016-2018

Methods For 252 of 345 consecutive participants (ages 33-96 years), BMSi was measured using the OsteoProbe® at the mid-tibia. Immediately following measurement, each participant used a visual analogue scale (0-10) to rate the level of discomfort that was anticipated and experienced, their initial reluctance towards the measurement and their willingness to repeat measurement.

Results Reasons for non-measurement in 92 men were needle phobia (n=8), discomfort after first indentation (n=5), skin infections (n=21), excessive soft tissues around the mid-tibia region (n=56), inability to provide informed consent (n=2). Among 252 men who had IMI measures, the expectation for pain during measurement was low (1.54 ± 1.56), as was actual pain experienced (0.38 ± 0.71). Reluctance to undergo measurement was low (0.34 ± 0.93). All participants indicated a willingness to have the measurement performed again. Mean (\pm SD) BMSi was 83.0 ± 6.4 (range 62.3-93.0).

Conclusion In this study, the procedure was well accepted by participants suggesting that IMI testing with the OsteoProbe® is feasible in a research setting.

Keywords: Microindentation, bone material strength index, fractures, OsteoProbe.

Strengths and limitations of this study

- This is the first study to examine the feasibility and tolerability of the OsteoProbe® in a population-based study setting.
- We evaluated the associations between BMSi and age in the largest population-based sample of men so far.
- We cannot exclude the possibility of some bias in the BMSi outcome because of non-participation.

Introduction

The most widely used clinical measurement for ascertainment of fracture risk is bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) (1). However, BMD does not fully explain fracture risk, as the largest absolute number of fragility fractures occur in people without severe deficits in BMD (2,3). Other determinants of bone strength such as bone geometry, microarchitecture and material properties are likely to contribute to fracture risk. Also, clinical factors such as a history of prior fracture, age, exposure to glucocorticoid and other medications, smoking and falls, can contribute independently to fracture risk, and these risk factors can be incorporated into fracture risk algorithms such as FRAX (4), the GARVAN algorithm (5) and the FRISK score (6). Therefore, the goal of much research is to develop techniques to better identify patients at risk of fracture. Using a novel device, the OsteoProbe®, to assess cortical bone material properties in vivo, impact microindentation (IMI) is one such technique (7). The OsteoProbe® measures Bone Material Strength Index (BMSi). This parameter quantifies how well a bone resists microindentation. BMSi is defined as 100 times the ratio of the indentation distance from the impact to a calibration material, PMMA (poly methyl methacrylate), divided by the indentation distance from the impact into

1
2
3 the bone. As the probe indents the bone, it induces microfractures. The more easily the bone
4 is fractured, the deeper the probe indents and the lower the BMSi. The technical aspects of
5 this device have been described in detail in the initial scientific instrumentation papers (7, 8).
6
7
8
9 The use of this device in research is growing; and BMSi has reportedly distinguished between
10 patients with different levels of fracture risk in some (9–12) but not all (13) studies, often
11 independently of BMD. These studies have been limited to relatively small sample sizes and
12 have often involved patients selected on the basis of disease.
13
14
15
16

17
18 Although these data suggest that BMSi might have clinical utility, future research is
19 warranted, particularly using unselected, population-based samples, to assess the performance
20 of IMI for identifying individuals at risk of fracture. As a new, minimally invasive
21 technology, it is important to gauge the tolerability of the IMI to better understand whether
22 participant groups and volunteers are likely to undergo the procedure in a research setting.
23 The aim of this study was to assess the feasibility and tolerability of the OsteoProbe® among
24 men enrolled in the Geelong Osteoporosis Study (GOS).
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **METHODS**

39 **Patient and Public involvement**

40
41 Participants received an information and consent form describing the research, but they were
42 not involved in the design or conduct of the study. All participants provided written consent.
43
44
45
46
47
48 Study findings are disseminated to participants via a research update, which is distributed
49 annually.
50
51
52
53
54
55
56
57
58
59
60

Source Population

The GOS is a population-based study situated in a defined region in south-eastern Australia, known as the Barwon Statistical Division (14). An age-stratified, randomly-selected cohort of 1540 men aged 20-97 years was recruited 2001-2006 using the electoral roll as the sampling frame. The cohort is being followed prospectively, with assessments every few years (14). This analysis focuses on the first 345 men assessed as part of the 15-year follow-up. In conjunction with other clinical measures including bone densitometry, participants were approached to undergo IMI testing and complete a short questionnaire about their experience relating to the technique. The study was approved by the Human Research Ethics Committee at Barwon Health (00/56-E7).

Bone material strength testing

IMI was performed by a trained operator using the OsteoProbe® (Active Life Scientific, Inc., CA, USA). The IMI procedure was explained to participants before measurements were made. They were informed that the procedure is a new technique that might assess the resistance of bones to fractures by inducing micro fractures on a small area of the tibia. Furthermore, participants were told the procedure is minimally invasive and does not affect the ability of the individual to walk immediately after. They were then given the option to participate or not participate in the study.

Participants who chose to participate in the study were positioned in decubitus supine position, with the leg to be measured rotated to orient the flat surface of the medial tibia diaphysis. The mid distance between the medial border of the tibia plateau and the medial malleolus were marked using a measuring tape. Following a disinfection of the area using a

1
2
3 70% isopropyl alcohol swab, 2% Lidocaine was administered by inserting a syringe both
4
5 subcutaneously and in the periosteal surface. A sterile probe was then inserted at the marked
6
7 mid diaphysis, piercing the skin and periosteum until reaching the bone cortex. While
8
9 maintaining probe contact with the bone surface, as well as orienting the probe
10
11 perpendicularly to the tibia surface, the outer housing of the device was slid towards the
12
13 subject's leg to initiate a measurement. After the first measurement, the probe was moved to
14
15 a new location, at least 2mm away from the prior measurement, to obtain another
16
17 measurement. In this study, at least 11 indentations were performed on each subject, of which
18
19 the first measurement was systematically disregarded followed by 10 valid test indentations.
20
21 A trained observer assisted the operator by ensuring that the probe was held perpendicular to
22
23 the tibial surface. The procedure was conducted according to internationally-recognised
24
25 recommendations for using the Osteoprobe RUO (15). Immediately following measurement,
26
27 each participant completed a questionnaire that asked them to rate on a visual analogue scale
28
29 (0-10) the level of pain that was anticipated, the level of pain that was experienced, their
30
31 initial reluctance towards the measurement and their willingness to undergo the measurement
32
33 again. The visual analogue scale is a valid, reliable and simple tool used to assess variations
34
35 in pain intensity (16,17)
36
37
38
39
40
41
42

43 **Statistical Analyses**

44
45
46 Comparisons between participants included and excluded in analyses were identified using t-
47
48 tests, and one-way ANOVA for differences in visual analogue scale responses across age
49
50 groups. Pearson product moment correlation was used to test for a linear correlation between
51
52 BMSi and age, weight, height and BMI. Statistical analyses were performed using Minitab
53
54 (version 17; Minitab, State College, PA).
55
56
57
58
59
60

RESULTS

Of 345 potential participants, exclusions were: needle phobia (n=8), existing skin infections (n=21), excessive soft tissues around mid-tibia region (n=56), due to discomfort (pressure, no pain) after the first indentation (n=5), unable to provide informed consent (n=2). One participant had IMI after skin infection had been treated. Therefore, 252 participants were included in the subsequent analyses.

Table 1 shows characteristics of study participants included and excluded in the analyses respectively. Participants ranged in age from 33 to 96 years.

BMSi ranged from 62.3 to 93.0. Mean BMSi±SD values for age groups 30-49, 50-69 and 70+ years were 81.9±5.4, 83.7±6.2 and 81.6±6.7, respectively. The average BMI of participants excluded due to soft tissues was 33.4 ± 5.6.

Tolerability scores were normally distributed and similar across all ages (Table 2, Figure 1). The expectation for pain during OsteoProbe® measurement was low, as was actual pain experienced and initial reluctance to undergo measurement. Tolerability of the OsteoProbe® measurement was high; all 252 participants who had a successful measurement indicated a willingness to undergo the measurement again. No adverse events were reported.

There were no correlations detected between BMSi and age ($r = 0.070$, $p = 0.270$), height ($r = 0.068$, $p = 0.281$) or weight ($r = -0.078$, $p = 0.215$); however, there was a negative correlation between BMSi and BMI ($r = -0.135$, $p = 0.032$).

Table 1 Characteristics of the study participants included and excluded in analyses

Characteristics	Included (n=252)	Excluded (n=92)	<i>p</i> Value
Age (yr)	63.2 ± 12.6	65.5 ± 15.6	0.163
Weight (kg)	81.2 ± 10.9	92.9 ± 19.1	<0.001
Height (cm)	174.3 ± 6.9	173.7 ± 10.3	0.983
Body Mass Index (kg/m ²)	26.7 ± 3.1	30.8 ± 7.8	<0.001

Data shown as mean (±SD)

Table 2: Tolerability scores for the whole group and according to age

	ALL ages	30-49 yr	50-69 yr	70+ yr	<i>p</i> Value
*Expectation for Pain	1.5 ± 1.6	2.0 ± 1.7	1.6 ± 1.6	1.2 ± 1.5	0.070
*Actual pain experienced	0.4 ± 0.7	0.4 ± 0.8	0.4 ± 0.8	0.3 ± 0.47	0.462
*Level of reluctance	0.3 ± 0.9	0.6 ± 1.0	0.4 ± 1.0	0.2 ± 0.6	0.136

*Questionnaire results for 0-10 visual analogue scale

DISCUSSION

In this study, we observed a high tolerability of IMI; reluctance to undergo the measurement was low and while there may be a potential concern for possible harm to the bone, all

1
2
3 participants who had a successful measurement indicated a willingness to undergo the
4
5 measurement again.
6

7
8 Although IMI is a minimally invasive procedure, with indentations on the scale of
9
10 micrometres, a valid concern is the tolerability of the procedure in a research setting,
11
12 particularly in studies that rely on participants/volunteers from the general population. We
13
14 report that testing with the device is feasible among participants in our population-based
15
16 study. The most common reason for exclusion was excessive soft tissues around the mid-
17
18 tibia. Other reasons for exclusions were skin infections, needle phobia, inability to provide
19
20 informed consent and discomfort after the first indentation, but these affected only one-tenth
21
22 of the study participants. Other potential contraindications include prior clinical or stress
23
24 fracture in the tibia diaphysis, focal tibial lesions and Paget's disease (15); however, to the
25
26 best of our knowledge, no studies have reported the actual number of exclusions based on
27
28 these criteria.
29
30

31
32 In studies using IMI, only two instances of adverse effects have been reported in the
33
34 literature, one associated with reaction to local anaesthetic and one mild skin infection, in
35
36 more than 1300 measured individuals (15). To our knowledge, we are the first to document
37
38 the tolerability of the procedure. Given that the anterior surface of the tibia is pre-treated
39
40 with a local anaesthetic delivered by subcutaneous injection through the skin and around the
41
42 periosteum and that the probe of the device is inserted through the skin, subcutaneous soft
43
44 tissue and periosteum into the cortical bone, it would seem likely that the procedure might
45
46 seem unpleasant for some study participants. High rates of refusal would introduce bias.
47
48 However, our results indicate that IMI is generally acceptable, at least for the participants of
49
50 our study implying that the technique shows promise as a measure of bone material properties
51
52 in a practical, safe and convenient manner.
53
54
55
56
57
58
59
60

1
2
3 Furthermore, we investigated participants from a wide age range and observed similar
4 tolerability scores across age groups ranging from 30-49, 50-69 to 70 years and older. The
5 men in the oldest category tended to report a lower expectation for pain, experienced less
6 pain and were less reluctant to undergo the measurement, but these differences were not
7 statistically significant.
8
9
10
11
12

13
14 In this study, we did not observe a correlation between BMSi and age, corresponding to two
15 studies by Duarte Sosa et al. in which no association was detected between age and BMSi in
16 42 Norwegian and 46 Spanish women (18) and among 30 women with previous stress
17 fractures and 30 normal controls (19). By contrast, an inverse association between age and
18 BMSi has been reported for 90 patients (male and female) with low bone mass, ($r = -0.539$;
19 $p < 0.001$) and in a case-control study of 48 acromegaly patients and 44 controls (male and
20 female), there was a positive association for patients with acromegaly ($r = 0.291$, $p = 0.045$)
21 and an inverse relationship for the controls ($r = -0.457$, $p = 0.002$) (20). The reason for lack
22 of consistency in results is not clear but likely reflects differences in study design and study
23 populations.
24
25
26
27
28
29
30
31
32
33
34
35

36
37 Moreover, no correlations of BMSi with height, weight were found but we observed a
38 negative correlation between BMSi and BMI. Similarly, Sundh et al. (21) reported a negative
39 correlation ($r = -0.17$, $p = 0.01$) between BMSi and BMI in a population-based study of 202
40 women between 75 and 80 years of age, and Rudang et al. (13) reported a weak inverse
41 correlation ($r = -0.14$, $p = 0.04$) between BMSi and weight in a population-based cohort of
42 211 women between 75 and 80 years of age, and, in accordance with our findings, there was
43 no association with height.
44
45
46
47
48
49
50
51

52
53 To our knowledge, this is the first study to examine the tolerability and feasibility of the
54 OsteoProbe® in a population-based study. Unlike most of the previous studies, this study is
55
56
57
58
59
60

1
2
3 population-based and not selected on the basis of disease status. The outcome will thus be
4 relevant for the general population. In this study, one operator conducted the IMI
5 measurements and an observer was present to ensure the procedure was performed according
6 to the standardised procedure.
7
8
9

10
11 However, we acknowledge the following limitations. IMI could not be performed in
12 individuals with substantial amounts of soft tissue around the mid-tibia region, nor in
13 individuals with skin disorders or infections in at the site of measurement and this may have
14 biased our results. It should be noted that there are also drawbacks with other technologies.
15 For example, a weight limitation (typically 120kg or 300lb) and narrow bed width (~60 cm)
16 necessitates exclusion of large individuals from assessment with DXA (22). Furthermore,
17 individuals with spinal abnormalities and those affected by devices such as plates, screws,
18 silicone implants and prostheses can compromise the interpretation of DXA scans (23–26). In
19 our study, we investigated men only, and recognise that the observations may not be
20 generalisable to women or other populations.
21
22
23
24
25
26
27
28
29
30
31
32
33

34 In conclusion, IMI was well accepted by participants suggesting that testing with the
35 OsteoProbe® is feasible in a research setting. Further assessment of the clinical utility of this
36 technology for assessing fracture risk is warranted and currently in progress.
37
38
39
40
41
42
43
44

45 **Funding Statement**

46
47 The Geelong Osteoporosis Study was supported by the National health and Medical Research
48 Council (NHMRC; projects 299831, 628582).and Amgen-GSK OA-ANZBMS, but they
49 played no role in the collection or interpretation of data.
50
51
52
53
54
55
56
57
58
59
60

Competing Interests

PGR is supported by Deakin University Postgraduate Industry Research Scholarship. KLH-K is supported by an Alfred Deakin Postdoctoral Research Fellowship. AD-P owns shares of Active Life Scientific, Inc., the manufacturer of the RPI device. MAK and JAP are recipients of grants from the NHMRC and Amgen-GSK OA-ANZBMS.

Authors' contributions

PGR performed the indentation measurements in the presence of another trained observer (KLH-K) and drafted the manuscript. KLH-K assisted with taking measurements and administered questionnaires. AD-P assisted with training to use the OsteoProbe device and provided advice on measurement technique. MAK and JAP conceived and designed the study. JAP secured ethics approval. All authors interpreted the data, guided and reviewed the manuscript. All authors read and approved the final manuscript.

Data sharing statement

The datasets used and analysed during the current study are available from the corresponding author on reasonable request. Requests can be sent to gos@barwonhealth.org.au.

Ethics approval and consent to participate

This project has been approved by Human Research Ethics Committee at Barwon Health. All participants gave written informed consent to participate in the study.

Acknowledgements

We thank Dr Peter Burks from Active Life Scientific, Inc. for his technical guidance

References

1. Allen MR, McNerny EMB, Organ JM, Wallace JM. True gold or pyrite: A review of reference point indentation for assessing bone mechanical properties in vivo. *J Bone Miner Res* 2015;30:1539–50.
2. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. *Osteoporos Int* 2006;17:1404–9.
3. Pasco JA, Lane SE, Brennan SL, Timney EN, Bucki-Smith G, Dobbins AG, et al. Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data. *Osteoporos Int*. 2014 ;25:857–62.
4. Watts NB. The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice. *J Womens Health*. 2011;20:525–31.
5. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen T V. Development of a nomogram for individualizing hip fracture risk in men and women. *Osteoporos Int* 2007;18:1109–17.
6. Henry MJ, Pasco JA, Sanders KM, Nicholson GC, Kotowicz MA. Fracture risk (FRISK) score : Geelong Osteoporosis Study. *Radiology*. 2006;241:190–6.
7. Randall C, Bridges D, Guerri R, Nogues X, Puig L, Torres E, et al. Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. *J Med Device* 2013;7:410051–6.
8. Bridges D, Randall C, Hansma PK. A new device for performing reference point

- 1
2
3 indentation without a reference probe. *Rev Sci Instrum.* 2012;83: 044301-8.
4
5
6 9. Malgo F, Hamdy NAT, Papapoulos SE, Appelman-Dijkstra NM. Bone material
7
8 strength as measured by microindentation in vivo is decreased in patients with fragility
9
10 fractures independently of bone mineral density. *J Clin Endocrinol Metab.*
11
12 2015;100:2039–45.
13
14
15 10. Malgo F. Bone material strength index as measured by impact microindentation is low
16
17 in patients with fractures irrespective of fracture site. *Osteoporosis International;*
18
19 2017;24:33–7.
20
21
22 11. Rozental TD, Walley KC, Demissie S, Caksa S, Martinez-betancourt A, Parker AM, et
23
24 al. Bone Material Strength Index as Measured by Impact Radius and Hip Fractures. *J*
25
26 *Bone Miner Res.* 2017;176:1–6.
27
28
29 12. With W, Radius D, Rozental TD, Walley KC, Demissie S, Caksa S. Bone Material
30
31 Strength Index as Measured by Impact Microindentation in Postmenopausal Bone
32
33 Material Strength Index as Measured by Impact. *J Bone Miner Res* 2018;33:621-626.
34
35
36 13. Rudäng R, Zoulakis M, Sundh D, Brisby H, Diez-Perez A, Johansson L, et al. Bone
37
38 material strength is associated with areal BMD but not with prevalent fractures in older
39
40 women. *Osteoporos Int.* 2016;27:1585–92.
41
42
43 14. Pasco JA, Nicholson GC, Kotowicz MA. Cohort Profile: Geelong Osteoporosis Study
44
45 *Int J Epidemiol* 2012; 41: 1565-1575.
46
47
48 15. Diez-Perez A, Bouxsein ML, Eriksen EF, Khosla S, Nyman JS, Papapoulos S, et al.
49
50 Technical note: Recommendations for a standard procedure to assess cortical bone at
51
52 the tissue-level in vivo using impact microindentation. *Bone Reports.* 2016;5:181–5.
53
54
55
56
57
58
59
60

16. Chapman CR, Casey KL, Dubner R, Foley KM, Gracely RH, Reading AE. Pain Measurement: an overview. *Pain*. 1985;22(1):1–31.
17. Gallagher EJ, Bijur PE, Latimer C, Silver W. Reliability and validity of a visual analog scale for acute abdominal pain in the ED. *Am J Emerg Med*. 2002;20(4):287–90.
18. Duarte Sosa D, Vilaplana L, Güerri R, Nogués X, Wang-Fagerland M, Diez-Perez A, et al. Are the High Hip Fracture Rates Among Norwegian Women Explained by Impaired Bone Material Properties? *J Bone Miner Res*. 2015;30:1784–9.
19. Duarte Sosa D, Fink Eriksen E. Women with previous stress fractures show reduced bone material strength. *Acta Orthop*. 2016;3674:1–6.
20. Malgo F, Hamdy NAT, Rabelink TJ, Kroon HM, Claessen KMJA, Pereira AM, et al. Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. *Eur J Endocrinol*. 2017;176:339–47.
21. Sundh D, Rudang R, Zoulakis M, Nilsson AG, Darelid A, Lorentzon M. A High Amount of Local Adipose Tissue Is Associated with High Cortical Porosity and Low Bone Material Strength in Older Women. *J Bone Miner Res*. 2016;31:749–57.
22. Rothney MP, Brychta RJ, Schaefer E V, Chen KY, Monica C. Body Composition Measured by Dual-energy X-ray Absorptiometry Half-body Scans in Obese Adults *Obesity (Silver Spring)* 2009;17(6):1281–6.
23. Gould H1, Brennan SL, Kotowicz MA, Nicholson GC PJ. Total and appendicular lean mass reference ranges for Australian men and women: the Geelong Osteoporosis Study. *Calcif Tissue Int*. 2014;94:363–72.
24. Henry MJ, Pasco JA, Korn S, Gibson JE. Bone mineral density reference ranges for

1
2
3 Australian men : Geelong Osteoporosis Study. *Osteoporos Int* 2010;909–17.
4

- 5
6 25. Kalichman L1, Li L, Kim DH, Guermazi A, Berkin V, O'Donnell CJ, Hoffmann U,
7
8 Cole R HD. Facet joint osteoarthritis and low back pain in the community-based
9
10 population. *Spine* 2008;33:2560–5.
11
12
13 26. Szulc P, Marchand, F, Duboeuf, F DP. Cross-sectional assessment of age-related bone
14
15 loss in men: the MINOS study. *Bone*. 2000;26:123–9.
16
17
18
19
20
21
22
23

24 **Figure 1: An interval plot of 0-10 Visual Analogue scale results, according to age**
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: An interval plot of 0-10 Visual Analogue scale results, according to age
101x135mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-7
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-7
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Feasibility and Tolerability of Bone Impact Microindentation Testing: a cross-sectional, population-based study in Australia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023959.R3
Article Type:	Research
Date Submitted by the Author:	13-Oct-2018
Complete List of Authors:	Rufus, Pamela; Deakin University Faculty of Health, School of Medicine Holloway, Kara; Deakin University - Geelong Waterfront Campus, Department of Medicine Diez-Perez, A; University of Barcelona Kotowicz, Mark; Barwon Health, Department of Endocrinology and Diabetes Pasco, Julie; The University of Melbourne, Clinical and Biomedical Sciences: Barwon Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology
Keywords:	EPIDEMIOLOGY, Bone diseases < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

1
2
3 **Feasibility and Tolerability of Bone Impact Microindentation Testing: a cross-sectional,**
4 **population-based study in Australia**
5

6
7 Pamela G Rufus¹, Kara L Holloway-Kew¹, Adolfo Diez-Perez², Mark A Kotowicz^{1,3,4}, Julie A
8
9 Pasco^{1,3,4,5}
10

11
12
13 *¹Deakin University, Geelong, VIC, Australia.*

14 *²Department of Internal Medicine, Hospital del Mar-IMIM, Autonomous University of Barcelona*
15 *and CIBERFES, Instituto Carlos III, Spain.*

16
17 *³Department of Medicine-Western Health, Melbourne Medical School, The University of*
18 *Melbourne, VIC, Australia.*

19 *⁴Barwon Health, Geelong, VIC, Australia.*

20
21 *⁵Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC,*
22 *Australia*
23

24
25
26
27
28
29 Corresponding author: Pamela G Rufus. Epi-Centre for Healthy Ageing. IMPACT Strategic
30 Research Centre, PO Box 281, School of Medicine, Deakin University. Geelong 3220 VIC,
31 Australia. Tel: +61 342153323. Email: prufus@deakin.edu.au
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives The OsteoProbe® measures bone material strength index (BMSi) of cortical bone in living humans using impact microindentation (IMI). Research using this minimally-invasive technique is expanding yet, to-date, there have been no reports about its feasibility in the research setting. In this study we assessed the feasibility and tolerability of using the OsteoProbe® in men enrolled in the Geelong Osteoporosis Study.

Design Cross-sectional analysis of data collected in a population-based study.

Setting Barwon Statistical Division, south-eastern Australia, 2016-2018

Methods For 252 of 345 consecutive participants (ages 33-96 years), BMSi was measured using the OsteoProbe® at the mid-tibia. Immediately following measurement, each participant used a visual analogue scale (0-10) to rate the level of discomfort that was anticipated and experienced, their initial reluctance towards the measurement and their willingness to repeat measurement.

Results Reasons for non-measurement in 92 men were needle phobia (n=8), discomfort after first indentation (n=5), skin infections (n=21), excessive soft tissues around the mid-tibia region (n=56), inability to provide informed consent (n=2). Among 252 men who had IMI measures, the expectation for pain during measurement was low (1.54 ± 1.56), as was actual pain experienced (0.38 ± 0.71). Reluctance to undergo measurement was low (0.34 ± 0.93). All participants indicated a willingness to have the measurement performed again. Mean (\pm SD) BMSi was 83.0 ± 6.4 (range 62.3-93.0).

1
2
3 **Conclusion** In this study, the procedure was well accepted by participants suggesting that IMI
4 testing with the OsteoProbe® is feasible in a research setting.
5
6
7

8 **Keywords: Microindentation, bone material strength index, fractures, OsteoProbe.**
9

10 **Strengths and limitations of this study**

11

- 12 • Feasibility and tolerability were assessed at the time of impact microindentation (IMI)
13 testing.
14
- 15 • The sample was selected at random from the general population and not on the basis of
16 disease status.
17
- 18 • One operator conducted the IMI measurements.
19
- 20 • This is the first study to report the actual number of IMI exclusions due to
21 contraindications.
22
- 23 • The findings might not be generalizable to women or other populations.
24
25
26
27
28
29
30
31
32
33
34

35 **Introduction**

36

37
38 The most widely used clinical measurement for ascertainment of fracture risk is bone mineral
39 density (BMD) measured by dual- energy X-ray absorptiometry (DXA) (1). However, BMD
40 does not fully explain fracture risk, as the largest absolute number of fragility fractures occur in
41 people without severe deficits in BMD (2,3). Other determinants of bone strength such as bone
42 geometry, microarchitecture and material properties are likely to contribute to fracture risk. Also,
43 clinical factors such as a history of prior fracture, age, exposure to glucocorticoid and other
44 medications, smoking and falls, can contribute independently to fracture risk, and these risk
45 factors can be incorporated into fracture risk algorithms such as FRAX (4), the GARVAN
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 algorithm (5) and the FRISK score (6). Therefore, the goal of much research is to develop
4
5 techniques to better identify patients at risk of fracture. Using a novel device, the OsteoProbe®,
6
7 to assess cortical bone material properties in vivo, impact microindentation (IMI) is one such
8
9 technique (7). The OsteoProbe® measures Bone Material Strength Index (BMSi). This parameter
10
11 quantifies how well a bone resists microindentation. BMSi is defined as 100 times the ratio of
12
13 the indentation distance from the impact to a calibration material, PMMA (poly methyl
14
15 methacrylate), divided by the indentation distance from the impact into the bone. As the probe
16
17 indents the bone, it induces microfractures. The more easily the bone is fractured, the deeper the
18
19 probe indents and the lower the BMSi. The technical aspects of this device have been described
20
21 in detail in the initial scientific instrumentation papers (7, 8). The use of this device in research is
22
23 growing; and BMSi has reportedly distinguished between patients with different levels of
24
25 fracture risk in some (9–12) but not all (13) studies, often independently of BMD. These studies
26
27 have been limited to relatively small sample sizes and have often involved patients selected on
28
29 the basis of disease.
30
31
32
33
34
35

36 Although these data suggest that BMSi might have clinical utility, future research is warranted,
37
38 particularly using unselected, population-based samples, to assess the performance of IMI for
39
40 identifying individuals at risk of fracture. As a new, minimally invasive technology, it is
41
42 important to gauge the tolerability of the IMI to better understand whether participant groups and
43
44 volunteers are likely to undergo the procedure in a research setting. The aim of this study was to
45
46 assess the feasibility and tolerability of the OsteoProbe® among men enrolled in the Geelong
47
48 Osteoporosis Study (GOS).
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Patient and Public involvement

Patients were not involved in the planning and design of this study.

Source Population

The GOS is a population-based study situated in a defined region in south-eastern Australia, known as the Barwon Statistical Division (14). An age-stratified, randomly-selected cohort of 1540 men aged 20-97 years was recruited 2001-2006 using the electoral roll as the sampling frame. The cohort is being followed prospectively, with assessments every few years (14). This analysis focuses on the first 345 men assessed as part of the 15-year follow-up. In conjunction with other clinical measures including bone densitometry, participants were approached to undergo IMI testing and complete a short questionnaire about their experience relating to the technique. The study was approved by the Human Research Ethics Committee at Barwon Health (00/56-E7). All participants provided informed consent.

Bone material strength testing

IMI was performed by a trained operator using the OsteoProbe® (Active Life Scientific, Inc., CA, USA). The IMI procedure was explained to participants before measurements were made. They were informed that the procedure is a new technique that might assess the resistance of bones to fractures by inducing micro fractures on a small area of the tibia. Furthermore, participants were told the procedure is minimally invasive and does not affect the ability of the

1
2
3 individual to walk immediately after. They were then given the option to participate or not
4
5 participate in the study.
6

7
8 Participants who chose to participate in the study were positioned in decubitus supine position,
9
10 with the leg to be measured rotated to orient the flat surface of the medial tibia diaphysis. The
11
12 mid distance between the medial border of the tibia plateau and the medial malleolus were
13
14 marked using a measuring tape. Following a disinfection of the area using a 70% isopropyl
15
16 alcohol swab, 2% Lidocaine was administered by inserting a syringe both subcutaneously and in
17
18 the periosteal surface. A sterile probe was then inserted at the marked mid diaphysis, piercing the
19
20 skin and periosteum until reaching the bone cortex. While maintaining probe contact with the
21
22 bone surface, as well as orienting the probe perpendicularly to the tibia surface, the outer housing
23
24 of the device was slid towards the subject's leg to initiate a measurement. After the first
25
26 measurement, the probe was moved to a new location, at least 2mm away from the prior
27
28 measurement, to obtain another measurement. In this study, at least 11 indentations were
29
30 performed on each subject, of which the first measurement was systematically disregarded
31
32 followed by 10 valid test indentations. A trained observer assisted the operator by ensuring that
33
34 the probe was held perpendicular to the tibial surface. The procedure was conducted according to
35
36 internationally-recognised recommendations for using the Osteoprobe RUO (15). Immediately
37
38 following measurement, each participant completed a questionnaire that asked them to rate on a
39
40 visual analogue scale (0-10) the level of pain that was anticipated, the level of pain that was
41
42 experienced, their initial reluctance towards the measurement and their willingness to undergo
43
44 the measurement again. The visual analogue scale is a valid, reliable and simple tool used to
45
46 assess variations in pain intensity (16,17)
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical Analyses

Comparisons between participants included and excluded in analyses were identified using t-tests, and one-way ANOVA for differences in visual analogue scale responses across age groups. Pearson product moment correlation was used to test for a linear correlation between BMSi and age, weight, height and BMI. Statistical analyses were performed using Minitab (version 17; Minitab, State College, PA).

RESULTS

Of 345 potential participants, exclusions were: needle phobia (n=8), existing skin infections (n=21), excessive soft tissues around mid-tibia region (n=56), due to discomfort (pressure, no pain) after the first indentation (n=5), unable to provide informed consent (n=2). One participant had IMI after skin infection had been treated. Therefore, 252 participants were included in the subsequent analyses.

Table 1 shows characteristics of study participants included and excluded in the analyses respectively. Participants ranged in age from 33 to 96 years.

BMSi ranged from 62.3 to 93.0. Mean BMSi \pm SD values for age groups 30-49, 50-69 and 70+ years were 81.9 \pm 5.4, 83.7 \pm 6.2 and 81.6 \pm 6.7, respectively. The average BMI of participants excluded due to soft tissues was 33.4 \pm 5.6.

Tolerability scores were normally distributed and similar across all ages (Table 2, Figure 1). The expectation for pain during OsteoProbe® measurement was low, as was actual pain experienced and initial reluctance to undergo measurement. Tolerability of the OsteoProbe® measurement was high; all 252 participants who had a successful measurement indicated a willingness to undergo the measurement again. No adverse events were reported.

There were no correlations detected between BMSi and age ($r = 0.070$, $p = 0.270$), height ($r = 0.068$, $p = 0.281$) or weight ($r = -0.078$, $p = 0.215$); however, there was a negative correlation between BMSi and BMI ($r = -0.135$, $p = 0.032$).

Table 1 Characteristics of the study participants included and excluded in analyses

Characteristics	Included (n=252)	Excluded (n=92)	<i>p</i> Value
Age (yr)	63.2 ± 12.6	65.5 ± 15.6	0.163
Weight (kg)	81.2 ± 10.9	92.9 ± 19.1	<0.001
Height (cm)	174.3 ± 6.9	173.7 ± 10.3	0.983
Body Mass Index (kg/m ²)	26.7 ± 3.1	30.8 ± 7.8	<0.001

Data shown as mean (±SD)

Table 2: Tolerability scores for the whole group and according to age

	ALL ages	30-49 yr	50-69 yr	70+ yr	<i>p</i> Value
*Expectation for Pain	1.5 ± 1.6	2.0 ± 1.7	1.6 ± 1.6	1.2 ± 1.5	0.070
*Actual pain experienced	0.4 ± 0.7	0.4 ± 0.8	0.4 ± 0.8	0.3 ± 0.5	0.462
*Level of reluctance	0.3 ± 0.9	0.6 ± 1.0	0.4 ± 1.0	0.2 ± 0.6	0.136

*Questionnaire results for 0-10 visual analogue scale

DISCUSSION

In this study, we observed a high tolerability of IMI; reluctance to undergo the measurement was low and while there may be a potential concern for possible harm to the bone, all participants who had a successful measurement indicated a willingness to undergo the measurement again.

Although IMI is a minimally invasive procedure, with indentations on the scale of micrometres, a valid concern is the tolerability of the procedure in a research setting, particularly in studies that rely on participants/volunteers from the general population. We report that testing with the device is feasible among participants in our population-based study. The most common reason for exclusion was excessive soft tissues around the mid-tibia. Other reasons for exclusions were skin infections, needle phobia, inability to provide informed consent and discomfort after the first indentation, but these affected only one-tenth of the study participants. Other potential contraindications include prior clinical or stress fracture in the tibia diaphysis, focal tibial lesions and Paget's disease (15); however, to the best of our knowledge, no studies have reported the actual number of exclusions based on these criteria.

1
2
3 In studies using IMI, only two instances of adverse effects have been reported in the literature,
4 one associated with reaction to local anaesthetic and one mild skin infection, in more than 1300
5 measured individuals (15). To our knowledge, we are the first to document the tolerability of the
6 procedure. Given that the anterior surface of the tibial is pre-treated with a local anaesthetic
7 delivered by subcutaneous injection through the skin and around the periosteum and that the
8 probe of the device is inserted through the skin, subcutaneous soft tissue and periosteum into the
9 cortical bone, it would seem likely that the procedure might seem unpleasant for some study
10 participants. High rates of refusal would introduce bias. However, our results indicate that IMI is
11 generally acceptable, at least for the participants of our study implying that the technique shows
12 promise as a measure of bone material properties in a practical, safe and convenient manner.
13
14

15
16
17 Furthermore, we investigated participants from a wide age range and observed similar
18 tolerability scores across age groups ranging from 30-49, 50-69 to 70 years and older. The men
19 in the oldest category tended to report a lower expectation for pain, experienced less pain and
20 were less reluctant to undergo the measurement, but these differences were not statistically
21 significant.
22
23

24
25
26 In this study, we did not observe a correlation between BMSi and age, corresponding to two
27 studies by Duarte Sosa et al. in which no association was detected between age and BMSi in 42
28 Norwegian and 46 Spanish women (18) and among 30 women with previous stress fractures and
29 30 normal controls (19). By contrast, an inverse association between age and BMSi has been
30 reported for 90 patients (male and female) with low bone mass, ($r = -0.539$; $p < 0.001$) and in a
31 case-control study of 48 acromegaly patients and 44 controls (male and female), there was a
32 positive association for patients with acromegaly ($r = 0.291$, $p = 0.045$) and an inverse
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 relationship for the controls ($r = -0.457, p = 0.002$) (20). The reason for lack of consistency in
4
5 results is not clear but likely reflects differences in study design and study populations.
6
7

8
9 Moreover, no correlations of BMSi with height, weight were found but we observed a negative
10
11 correlation between BMSi and BMI. Similarly, Sundh et al. (21) reported a negative correlation
12
13 ($r = -0.17, p = 0.01$) between BMSi and BMI in a population-based study of 202 women between
14
15 75 and 80 years of age, and Rudang et al. (13) reported a weak inverse correlation ($r = -0.14, p =$
16
17 0.04) between BMSi and weight in a population-based cohort of 211 women between 75 and 80
18
19 years of age, and, in accordance with our findings, there was no association with height.
20
21

22
23 To our knowledge, this is the first study to examine the tolerability and feasibility of the
24
25 OsteoProbe® in a population-based study. Unlike most of the previous studies, this study is
26
27 population-based and not selected on the basis of disease status. The outcome will thus be
28
29 relevant for the general population. In this study, one operator conducted the IMI measurements
30
31 and an observer was present to ensure the procedure was performed according to the
32
33 standardised procedure.
34
35

36
37 However, we acknowledge the following limitations. IMI could not be performed in individuals
38
39 with substantial amounts of soft tissue around the mid-tibia region, nor in individuals with skin
40
41 disorders or infections in at the site of measurement and this may have biased our results. It
42
43 should be noted that there are also drawbacks with other technologies. For example, a weight
44
45 limitation (typically 120kg or 300lb) and narrow bed width (~60 cm) necessitates exclusion of
46
47 large individuals from assessment with DXA (22). Furthermore, individuals with spinal
48
49 abnormalities and those affected by devices such as plates, screws, silicone implants and
50
51 prostheses can compromise the interpretation of DXA scans (23–26). In our study, we
52
53
54
55
56
57
58
59
60

1
2
3 investigated men only, and recognise that the observations may not be generalisable to women or
4
5 other populations.
6
7

8 In conclusion, IMI was well accepted by participants suggesting that testing with the
9
10 OsteoProbe® is feasible in a research setting. Further assessment of the clinical utility of this
11
12 technology for assessing fracture risk is warranted and currently in progress.
13
14
15
16
17
18
19
20
21

22 **Funding Statement**

23
24
25 The Geelong Osteoporosis Study was supported by the National health and Medical Research
26
27 Council (NHMRC; projects 299831, 628582).and Amgen-GSK OA-ANZBMS, but they played
28
29 no role in the collection or interpretation of data.
30
31
32
33
34
35
36

37 **Competing Interests**

38
39 PGR is supported by Deakin University Postgraduate Industry Research Scholarship. KLH-K is
40
41 supported by an Alfred Deakin Postdoctoral Research Fellowship. AD-P owns shares of Active
42
43 Life Scientific, Inc., the manufacturer of the RPI device. MAK and JAP are recipients of grants
44
45 from the NHMRC and Amgen-GSK OA-ANZBMS.
46
47
48
49

50 **Authors' contributions**

51
52 PGR performed the indentation measurements in the presence of another trained observer (KLH-
53
54 K) and drafted the manuscript. KLH-K assisted with taking measurements and administered
55
56
57
58
59
60

1
2
3 questionnaires. AD-P assisted with training to use the OsteoProbe device and provided advice on
4 measurement technique. MAK and JAP conceived and designed the study. JAP secured ethics
5 approval. All authors interpreted the data, guided and reviewed the manuscript. All authors read
6 and approved the final manuscript.
7
8
9
10
11
12

13 **Data sharing statement**

14
15
16 The datasets used and analysed during the current study are available from the corresponding
17 author on reasonable request. Requests can be sent to gos@barwonhealth.org.au.
18
19
20
21

22 **Ethics approval and consent to participate**

23
24 This project has been approved by Human Research Ethics Committee at Barwon Health. All
25 participants gave written informed consent to participate in the study.
26
27
28
29

30 **Acknowledgements**

31 We thank Dr Peter Burks from Active Life Scientific, Inc. for his technical guidance
32
33
34
35
36
37
38
39

40 **References**

- 41
42
43 1. Allen MR, McNerny EMB, Organ JM, Wallace JM. True gold or pyrite: A review of
44 reference point indentation for assessing bone mechanical properties in vivo. *J Bone*
45 *Miner Res* 2015;30:1539–50.
46
47
48
49
50
51 2. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The
52 population burden of fractures originates in women with osteopenia, not osteoporosis.
53 *Osteoporos Int* 2006;17:1404–9.
54
55
56
57
58
59
60

3. Pasco JA, Lane SE, Brennan SL, Timney EN, Bucki-Smith G, Dobbins AG, et al. Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data. *Osteoporos Int*. 2014 ;25:857–62.
4. Watts NB. The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice. *J Womens Health*. 2011;20:525–31.
5. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen T V. Development of a nomogram for individualizing hip fracture risk in men and women. *Osteoporos Int* 2007;18:1109–17.
6. Henry MJ, Pasco JA, Sanders KM, Nicholson GC, Kotowicz MA. Fracture risk (FRISK) score : Geelong Osteoporosis Study. *Radiology*. 2006;241:190–6.
7. Randall C, Bridges D, Guerri R, Nogues X, Puig L, Torres E, et al. Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. *J Med Device* 2013;7:410051–6.
8. Bridges D, Randall C, Hansma PK. A new device for performing reference point indentation without a reference probe. *Rev Sci Instrum*. 2012;83: 044301-8.
9. Malgo F, Hamdy NAT, Papapoulos SE, Appelman-Dijkstra NM. Bone material strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of bone mineral density. *J Clin Endocrinol Metab*. 2015;100:2039–45.
10. Malgo F. Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site. *Osteoporosis International*; 2017;2433–7.
11. Rozental TD, Walley KC, Demissie S, Caksa S, Martinez-betancourt A, Parker AM, et al.

- 1
2
3 Bone Material Strength Index as Measured by Impact Radius and Hip Fractures. *J Bone*
4
5 *Miner Res.* 2017;176:1–6.
6
7
8
9 12. With W, Radius D, Rozental TD, Walley KC, Demissie S, Caksa S. Bone Material
10
11 Strength Index as Measured by Impact Microindentation in Postmenopausal Bone
12
13 Material Strength Index as Measured by Impact. *J Bone Miner Res* 2018;33:621-626.
14
15
16 13. Rudäng R, Zoulakis M, Sundh D, Brisby H, Diez-Perez A, Johansson L, et al. Bone
17
18 material strength is associated with areal BMD but not with prevalent fractures in older
19
20 women. *Osteoporos Int.* 2016;27:1585–92.
21
22
23
24 14. Pasco JA, Nicholson GC, Kotowicz MA. Cohort Profile: Geelong Osteoporosis Study *Int*
25
26 *J Epidemiol* 2012; 41: 1565-1575.
27
28
29 15. Diez-Perez A, Bouxsein ML, Eriksen EF, Khosla S, Nyman JS, Papapoulos S, et al.
30
31 Technical note: Recommendations for a standard procedure to assess cortical bone at the
32
33 tissue-level in vivo using impact microindentation. *Bone Reports.* 2016;5:181–5.
34
35
36
37 16. Chapman CR, Casey KL, Dubner R, Foley KM, Gracely RH, Reading AE. Pain
38
39 Measurement: an overview. *Pain.* 1985;22(1):1–31.
40
41
42
43 17. Gallagher EJ, Bijur PE, Latimer C, Silver W. Reliability and validity of a visual analog
44
45 scale for acute abdominal pain in the ED. *Am J Emerg Med.* 2002;20(4):287–90.
46
47
48 18. Duarte Sosa D, Vilaplana L, Güerri R, Nogués X, Wang-Fagerland M, Diez-Perez A, et
49
50 al. Are the High Hip Fracture Rates Among Norwegian Women Explained by Impaired
51
52 Bone Material Properties? *J Bone Miner Res.* 2015;30:1784–9.
53
54
55
56 19. Duarte Sosa D, Fink Eriksen E. Women with previous stress fractures show reduced bone
57
58
59

- material strength. *Acta Orthop*. 2016;3674:1–6.
20. Malgo F, Hamdy NAT, Rabelink TJ, Kroon HM, Claessen KMJA, Pereira AM, et al. Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. *Eur J Endocrinol*. 2017;176:339–47.
21. Sundh D, Rudang R, Zoulakis M, Nilsson AG, Darelid A, Lorentzon M. A High Amount of Local Adipose Tissue Is Associated with High Cortical Porosity and Low Bone Material Strength in Older Women. *J Bone Miner Res*. 2016;31:749–57.
22. Rothney MP, Brychta RJ, Schaefer E V, Chen KY, Monica C. Body Composition Measured by Dual-energy X-ray Absorptiometry Half-body Scans in Obese Adults *Obesity (Silver Spring)* 2009;17(6):1281–6.
23. Gould H1, Brennan SL, Kotowicz MA, Nicholson GC PJ. Total and appendicular lean mass reference ranges for Australian men and women: the Geelong Osteoporosis Study. *Calcif Tissue Int*. 2014;94:363–72.
24. Henry MJ, Pasco JA, Korn S, Gibson JE. Bone mineral density reference ranges for Australian men : Geelong Osteoporosis Study. *Osteoporos Int* 2010;909–17.
25. Kalichman L1, Li L, Kim DH, Guermazi A, Berkin V, O'Donnell CJ, Hoffmann U, Cole R HD. Facet joint osteoarthritis and low back pain in the community-based population. *Spine* 2008;33:2560–5.
26. Szulc P, Marchand, F, Duboeuf, F DP. Cross-sectional assessment of age-related bone loss in men: the MINOS study. *Bone*. 2000;26:123–9.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: An interval plot of 0-10 Visual Analogue scale results, according to age

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2018-023959 on 22 December 2018. Downloaded from <http://bmjopen.bmj.com/> on April 16, 2024 by guest. Protected by copyright.




Figure 1: An interval plot of 0-10 Visual Analogue scale results, according to age

101x135mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A

Continued on next page

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-7
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-7
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.